| Type | Title | Date Released | |
|---|---|---|---|
8-K | Glucotrack, Inc. Receives Nasdaq Delisting Notice for Failure to Meet Minimum Bid Price Requirement | ||
8-K | Glucotrack, Inc. Unaudited Pro Forma Financial Information Regarding Merger with Lokahi Therapeutics, Inc. | ||
8-K | 1-for-2 Reverse Stock Split Set to Take Effect October 26 to Help Regain Nasdaq’s Minimum Bid Compliance | ||
8-K | Glucotrack Enters Into Waiver Agreement and Agrees to Issue New Warrants | ||
PRE 14A | Form PRE 14A | ||
S-1/A | SHARE RESALE REGISTRATION + SPA | Shares: 43,223,705 | ||
425 | Form 425 | ||
8-K/A | Unaudited pro forma financials reflect merger, $53.5 million combined assets, and $19.7 million six-month net loss. | ||
8-K | Glucotrack, Inc. Files Form 8-K Detailing Note and Warrant Amendments and Full Repayment of Bridge Notes | ||
424B5 | REGISTERED OFFERING | ||
8-K | Glucotrack, Inc. Announces $3.1 Million Registered Direct Offering | ||
425 | Form 425 |
